Trial · NCT06772272
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Perioperative RBC transfusion requirement | Discharge or within 4 weeks of hospitalization (whichever comes first) | The incidence of the composite outcome of perioperative transfusion requirement (defined as the occurrence of one or more of the following events): * Red blood cell transfusion * Perioperative lowest hemoglobin level below 80 g/L |
| Secondary | Blood Transfusion Rate | Discharge or within 4 weeks of hospitalization (whichever comes first) | The percentage of participants in each group requiring red blood cell transfusion during the perioperative period. |
| Secondary | Volume of Blood Transfused | Discharge or within 4 weeks of hospitalization (whichever comes first) | The total volume of red blood cells transfused in units per participant during the perioperative period. |
| Secondary | Hemoglobin Levels at Different Time Points | Baseline, pre-surgery, during surgery, 1, 3, 5, and 28 days post-surgery, and at 1 month and 6 months follow-up. | Hemoglobin levels will be measured at key time points to assess changes, including: at baseline (enrollment), pre-surgery, during surgery, at 1, 3, 5, 28 days post-surgery, and at 1 month and 6 months follow-up visits to monitor longer-term effects. |
| Secondary | Ferritin and Anemia-Related Blood Tests | Baseline, pre-surgery, 1, 3, 5, 28 days post-surgery. | Levels of ferritin and other biomarkers related to anemia will be measured, including iron, transferrin, and vitamin B12, to assess the impact of Roxadustat on anemia. |
| Secondary | Length of Hospital Stay | Discharge or within 4 weeks of hospitalization (whichever comes first) | The total duration of hospitalization for each participant, measured in days. |
| Secondary | Hospitalization Costs | Discharge or within 4 weeks of hospitalization (whichever comes first) | The total cost of the hospital stay for each participant, including all treatments and care. |
| Secondary | Thrombotic Events | From admission to discharge (up to 28 days) and at follow-up visits at 1 and 6 months post-surgery. | Incidence of thrombotic events, including deep vein thrombosis, myocardial infarction, ischemic stroke, and pulmonary embolism. |
| Secondary | Hyperkalemia | From the start of medication until 3 days after the end of treatment. | Occurrence of elevated potassium levels (hyperkalemia) during the perioperative period. |
| Secondary | Metabolic Acidosis | From the start of medication until 3 days after the end of treatment. | Incidence of metabolic acidosis as measured by blood gas analysis. |
| Secondary | Neurological Side Effects (Dizziness, Drowsiness, Seizures) | From the start of medication until 3 days after the end of treatment. | Occurrence of neurological side effects, including dizziness, drowsiness, or seizures, reported by participants or physicians. |
| Secondary | Gastrointestinal Side Effects | From the start of medication until 3 days after the end of treatment. | Incidence of gastrointestinal side effects, including nausea, vomiting, indigestion, and diarrhea. |
| Secondary | Limb Edema | From the start of medication until 3 days after the end of treatment. | Occurrence of edema in the limbs during the medication period. |
| Secondary | Upper Respiratory Tract Infections | From the start of medication until 3 days after the end of treatment. | Incidence of upper respiratory tract infections during the medication period. |
| Secondary | Allergic Reactions | From the start of medication until 3 days after the end of treatment. | Occurrence of allergic reactions to the medication or other substances during the medication period. |
| Secondary | Insomnia | From the start of medication until 3 days after the end of treatment. | Incidence of insomnia reported by participants during the medication period. |
| Secondary | Acute Kidney Injury | From the start of surgery until hospital discharge or within 4 weeks post-surgery. | Incidence of acute kidney injury as defined by KDIGO criteria. |
| Secondary | Postoperative Infections | From the start of surgery until hospital discharge or within 4 weeks post-surgery. | Incidence of infections following surgery, including sepsis and pneumonia. |
| Secondary | Mortality Rate | From the start of surgery until follow-up visits at 1 and 6 months post-surgery. | All-cause mortality during the perioperative period and follow-up. |
| Secondary | MACE (Major Adverse Cardiovascular Events) | From the start of surgery until follow-up visits at 1 and 6 months post-surgery. | Incidence of MACE, including all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06772272/registered